New genetic test for baldness launched by HairDX

November 2008

PharmaGenoma, Inc. and its subsidiary HairDX, LLC have unveiled the next generation of its genetic screening test for male pattern baldness.

Using the HairDX test, a physician can tell a man who tests positive for the high risk genetic variant that he has approximately a 70% chance of going bald. Similarly, a physician can tell a man who tests negative for the high risk genetic variant that he has approximately a 70% chance of not going bald.

“The next generation test report is based on a pooled data model from multiple peer reviewed studies of over 2,000 Caucasian men. The studies demonstrated the association between the genetic variants measured by the HairDX genetic screening test and the development of Androgenetic Alopecia in men,” says Andy Goren, HairDX Chairman and Co-Founder.

In addition to the improved clinical validity and utility, the HairDX genetic test now includes genetic markers on the Androgen Receptor (AR) gene as well as on Chromosome 20.

"A recent study demonstrated that Propecia, the only FDA approved oral prescription medication for the treatment of male pattern baldness, is effective at preventing hair loss over a period of several years. Doctors using the HairDX genetic screening test can offer a treatment plan to prevent hair loss in men of all ages before any visible signs of hair loss," says Dr. Sharon Keene, Chief Medical Officer for HairDX and former Chairman of the Annual Scientific Committee of the International Society of Hair Restoration Surgeons.

Visible signs of hair loss usually mean that a man has already lost up to 50% of their hair. Early detection via the HairDX genetic screening test provides an opportunity for intervention and treatment before it is too late.

The next generation screening test identifies approximately 70% of men that will benefit from early treatment. As with any screening test, some men will be identified for treatment even though they may not go bald. Confirmatory tests by a qualified physician will eliminate unnecessary treatment.

The HairDX test is available through qualified physicians’ offices in the US.

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.	Your browser does not support inline frames or is currently configured not to display inline frames. New genetic test for baldness launched by HairDX November 2008 PharmaGenoma, Inc. and its subsidiary HairDX, LLC have unveiled the next generation of its genetic screening test for male pattern baldness. Using the HairDX test, a physician can tell a man who tests positive for the high risk genetic variant that he has approximately a 70% chance of going bald. Similarly, a physician can tell a man who tests negative for the high risk genetic variant that he has approximately a 70% chance of not going bald. “The next generation test report is based on a pooled data model from multiple peer reviewed studies of over 2,000 Caucasian men. The studies demonstrated the association between the genetic variants measured by the HairDX genetic screening test and the development of Androgenetic Alopecia in men,” says Andy Goren, HairDX Chairman and Co-Founder. In addition to the improved clinical validity and utility, the HairDX genetic test now includes genetic markers on the Androgen Receptor (AR) gene as well as on Chromosome 20. "A recent study demonstrated that Propecia, the only FDA approved oral prescription medication for the treatment of male pattern baldness, is effective at preventing hair loss over a period of several years. Doctors using the HairDX genetic screening test can offer a treatment plan to prevent hair loss in men of all ages before any visible signs of hair loss," says Dr. Sharon Keene, Chief Medical Officer for HairDX and former Chairman of the Annual Scientific Committee of the International Society of Hair Restoration Surgeons. Visible signs of hair loss usually mean that a man has already lost up to 50% of their hair. Early detection via the HairDX genetic screening test provides an opportunity for intervention and treatment before it is too late. The next generation screening test identifies approximately 70% of men that will benefit from early treatment. As with any screening test, some men will be identified for treatment even though they may not go bald. Confirmatory tests by a qualified physician will eliminate unnecessary treatment. The HairDX test is available through qualified physicians’ offices in the US. Bookmark this page Your browser does not support inline frames or is currently configured not to display inline frames. To top	Your browser does not support inline frames or is currently configured not to display inline frames.